Herpes Zoster
Conditions
Brief summary
The purpose of the sutdy is to evaluate the protective efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) (hereinafter referred to as "the investigational vaccine") in preventing herpes zoster at 13-36 months after complete immunization with the 0- and 2-month immunization schedule in individuals aged 40 years and older.
Interventions
BIOLOGICALRecombinant Zoster Vaccine (CHO Cell)
0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105. Intramuscular injection
BIOLOGICALNaCl solution Placebo
0.5 mL per dose, containing 4.5 mg sodium chloride. Intramuscular injection
Sponsors
MAXVAX Biotechnology Limited Liability Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Participants in the MKKCT-100-003 study who have completed two doses of the investigational vaccine; 2. Males or females able to provide legal identity certificate; 3. Participants voluntarily agree to participate in the study, and sign the informed consent form; 4. Able to understand the study procedures and participate in all scheduled follow-up visits, and able to comply with the protocol requirements (such as cooperating in filling out questionnaires/scales, and being regularly contacted during the study for evaluation, etc.).
Exclusion criteria
1. Participants who plan to use any products (drugs, vaccines, or medical devices) other than the investigational product for the prevention of VZV infection before signing the informed consent form or during the study period; 2. Participants with a history of herpes zoster; 3. Participants with any confirmed or suspected immunosuppressive or immunodeficiency condition caused by diseases (e.g., malignant tumors, human immunodeficiency virus infections, etc.) or immunosuppressive/cytotoxic treatments (e.g., medications used during cancer chemotherapy, organ transplantation, or treatment of autoimmune diseases); 4. Participants who are currently participating in or plan to participate in other clinical trials during the study; 5. Significant underlying diseases or any other condition that, in the opinion of the investigator, may prevent completion of the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The person-year incidence of confirmed herpes zoster cases among individuals aged 40 years and older, 13 to 36 months after completing the full vaccination course with the investigational vaccine according to the 0- and 2-month immunization schedule. | At 13~36 months after the last vaccination | A suspected case of HZ was confirmed either: by Polymerase Chain Reaction (PCR) or by the Endpoint Adjudication Committee (EAC), consisting of physicians with HZ expertise. |
Secondary
| Measure | Time frame |
|---|---|
| The person-year incidence of confirmed herpes zoster cases among individuals aged 40 years and older: from 30 days to 36 months after completing the full vaccination course, and the annual person-year incidence from 30 days after the full vaccination. | At 30 days~36 months after the last vaccination. |
| The person-year incidence rate of confirmed Herpes Zoster (HZ) cases during the periods of 30 days to 36 months, 13 to 36 months, and annually after 30 days post full-course immunization, in populations of different age groups. | 30 days to 36 months, 13 to 36 months, and 30 days after the last vaccination. |
| Incidence of any and severe Postherpetic Neuralgia (PHN) cases per person years in subjects aged 40 years and older, 40-49years , 50-59 years , 60-69 years and ≥70 years , with confirmed HZ. | 30 days after the last vaccination. |
Countries
China
Outcome results
None listed